I agree that this site is using cookies. You can find further informations here.
X
Kitanaka, Chifumi
123  results:
Search for persons X
?
1

The MDM2–p53 Axis Represents a Therapeutic Vulnerability Un..:

Nakagawa-Saito, Yurika ; Mitobe, Yuta ; Togashi, Keita...
International Journal of Molecular Sciences.  25 (2024)  7 - p. 3948 , 2024
Link: https://doi.org/10.3390/..
 
?
2

CTNI-68. PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFO..:

Narita, Yoshitaka ; Ohno, Makoto ; Kitanaka, Chifumi...
Neuro-Oncology.  25 (2023)  Supplement_5 - p. v92-v93 , 2023
Link: https://doi.org/10.1093/..
 
?
3

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor ..:

Mitobe, Yuta ; Suzuki, Shuhei ; Nakagawa-Saito, Yurika...
Cancers.  15 (2023)  17 - p. 4326 , 2023
Link: https://doi.org/10.3390/..
 
?
4

CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and In..:

Togashi, Keita ; Suzuki, Shuhei ; Mitobe, Yuta...
Cancers.  16 (2023)  1 - p. 118 , 2023
Link: https://doi.org/10.3390/..
 
?
5

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway..:

Mitobe, Yuta ; Suzuki, Shuhei ; Nakagawa-Saito, Yurika...
Biomedicines.  11 (2023)  7 - p. 1967 , 2023
Link: https://doi.org/10.3390/..
 
?
6

10008-CBMS-1 THE NOVEL MDM4 INHIBITOR CEP-1347 ACTIVATES TH..:

Mitobe, Yuta ; Sonoda, Yukihiko ; Kitanaka, Chifumi
Neuro-Oncology Advances.  5 (2023)  Supplement_5 - p. v2-v2 , 2023
Link: https://doi.org/10.1093/..
 
?
7

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the ..:

Nakagawa-Saito, Yurika ; Mitobe, Yuta ; Suzuki, Shuhei...
International Journal of Molecular Sciences.  24 (2023)  13 - p. 10817 , 2023
Link: https://doi.org/10.3390/..
 
?
8

10014-CBMS-2 CONCURRENT TARGETING OF MDM4 AND MDM2 USING CE..:

Mitobe, Yuta ; Sonoda, Yukihiko ; Kitanaka, Chifumi
Neuro-Oncology Advances.  5 (2023)  Supplement_5 - p. v2-v3 , 2023
Link: https://doi.org/10.1093/..
 
?
9

Gemcitabine Cooperates with Everolimus to Inhibit the Growt..:

Yamamoto, Masahiro ; Suzuki, Shuhei ; Togashi, Keita...
Cancers.  14 (2022)  7 - p. 1706 , 2022
Link: https://doi.org/10.3390/..
 
?
10

Inhibition of the Phospholipase Cε–c-Jun N-Terminal Kinase ..:

Okada, Masashi ; Nakagawa-Saito, Yurika ; Mitobe, Yuta...
International Journal of Molecular Sciences.  23 (2022)  15 - p. 8785 , 2022
Link: https://doi.org/10.3390/..
 
?
11

Clinicopathological risk factors for a poor prognosis of pr..:

Asano, Kenichiro ; Yamashita, Yoji ; Ono, Takahiro...
Brain Tumor Pathology.  39 (2022)  3 - p. 139-150 , 2022
Link: https://doi.org/10.1007/..
 
?
12

ACT-19 A REPORT OF PHASE I PART OF PHASE I/II STUDY OF MAIN..:

Ohno, Makoto ; Kitanaka, Chifumi ; Miyakita, Yasuji...
Neuro-Oncology Advances.  4 (2022)  Supplement_3 - p. iii9-iii9 , 2022
Link: https://doi.org/10.1093/..
 
?
13

HDAC Class I Inhibitor Domatinostat Preferentially Targets ..:

Nakagawa-Saito, Yurika ; Saitoh, Shinichi ; Mitobe, Yuta...
International Journal of Molecular Sciences.  23 (2022)  15 - p. 8084 , 2022
Link: https://doi.org/10.3390/..
 
?
14

Metformin with Temozolomide for Newly Diagnosed Glioblastom..:

Ohno, Makoto ; Kitanaka, Chifumi ; Miyakita, Yasuji...
Cancers.  14 (2022)  17 - p. 4222 , 2022
Link: https://doi.org/10.3390/..
 
?
15

The Real-World status and risk factors for a poor prognosis..:

Asano, Kenichiro ; Yamashita, Yoji ; Ono, Takahiro...
International Journal of Clinical Oncology.  27 (2021)  1 - p. 77-94 , 2021
Link: https://doi.org/10.1007/..
 
1-15